Evolving Colorectal Cancer Treatment Landscape

Opinion
Video

Colorectal cancer specialists discuss the effect of the SUNLIGHT trial data on the overall treatment and research landscapes.

This is a synopsis of an Insights series featuring Marwan G. Fakih, MD, of City of Hope, and Atif Hussein, MD, MMM, FACP, of Memorial Healthcare System.

Dr Fakih stated the phase 3 SUNLIGHT trial’s 10.8-month median overall survival with trifluridine/tipiracil plus bevacizumab represents an unprecedented finding for the refractory metastatic colorectal cancer third-line setting in a phase 3 study.

Considering the impressive survival benefit and hazard ratios under 0.5 for overall and progression-free survival, Dr Hussein suggested exploring the combination’s earlier introduction rather than reserving it for the third line. However, he agreed that the third line clearly represents the optimal placement currently, eliminating any debate with regorafenib as fourth-line monotherapy.

Nonetheless, Dr. Hussein remains intrigued by the unique chemotherapy backbone synergy this regimen displayed, motivating investigation of even further optimization in earlier lines. For future third-line colorectal cancer trials, Dr Fakih established the SUNLIGHT data necessitate utilizing trifluridine/tipiracil plus bevacizumab therapy as the minimum comparator arm given its new benchmark status.

In summary, Drs Fakih and Hussein concurred that beyond definitively establishing a new standard of care for refractory disease, the noteworthy SUNLIGHT trial results set a higher bar for survival outcomes in this setting. The promising chemotherapy backbone observed may justify earlier introduction pending additional research. Regardless, they agreed future third-line trial designs can no longer include inferior comparators, demanding comparison to trifluridine/tipiracil and bevacizumab combination therapy given the new overall survival yardstick demonstrated in refractory metastatic colorectal cancer management.

*Video synopsis is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content